Tag: Phase II Trial

Revolo Biotherapeutics '1104

Peptide Shows Promise as an Allergen-Agnostic Treatment for Food Allergy

Revolog presents new data demonstrating long-lasting effect of '1104 candidate.
SLIT

Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting

A unique peanut allergy immunotherapy continues to show promise for children.
Boiled Peanuts

Study of Boiled Peanuts Show Promise for Treatment of Peanut Allergy

OIT with boiled followed by roasted peanuts appears effective with a favorable safety profile.
Aquestive AQST-109 Epinephrine Film

Aquestive Receives Positive FDA Response to Epinephrine Sublingual Film Phase 2...

Response confirms approach and supports the characterization of their novel drug platform.
Aquestive's AQST-109

Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...

The company announced topline results from their EPIPHAST II study.
Baby

Siolta Begins Phase 2 Study in Newborns of Bacteria Consortia ...

STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
Aquestive AQST-109 Epinephrine Film

Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial

Phase 2 study continues to show AQST-109 is safe and well tolerated.
OpenBiome Fecal Capsules

Positive Early Results with Fecal Microbiota Therapy for Peanut-Allergic Patients

Encapsulated stool from non-allergic donors alters the immune system and increases tolerance to peanuts.
Revolo Therapeutics

Revolo Biotherapeutics Announces Open Enrollment for Phase 2 Clinical Trial of...

Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.